单位：[1]TianjinMedical University Cancer Institute and Hospital, Tianjin, China, Tianjin/CN[2]Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai/CN[3]Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai/CN[4]Department of Internal Medicine, Affiliated Cancer Hospital ofZhengzhou University, Henan Cancer Hospital, Zhengzhou/CN河南省肿瘤医院[5]PekingUnion Medical College Hospital, Beijing/CN[6]Linyi City Tumor Hospital,Linyi/CN[7]Shandong Province Tumor Hospital, Jinan/CN[8]Department ofThoracic Surgery, Guangzhou Medical University First Affiliated Hospital,Guangzhou 510120, China, Guangzhou/CN[9]Department of MedicalOncology, Cancer Institute and Hospital, Chinese Academy of MedicalSciences and Peking Union Medical College, Beijing Key Laboratory ofClinical Study on Anticancer Molecular Targeted Drugs, Beijing/CN[10]Thoracic Oncology, Jilin Provincial Cancer Hospital, Changchun/CN[11]Lanzhou Military General Hospital, Lanzhou/CN[12]Qilu Hospital ofShandong University, Jinan/CN[13]Hunan Province Tumor Hospital,Changsha/CN[14]First Affiliated Hospital of Xi’An Jiaotong University,Xian/CN[15]Tangdu Hospital, Fourth Military Medical University, Xian/CN[16]Yunnan Cancer Hospital, Kunming/CN[17]Beijing Chest Hospital,Capital Medical University, Beijing/CN,[18]Jiangxi Cancer Hospital,Nanchang/CN[19]Respiratory Diseases, The First Affiliated Hospital,College of Medicine, Zhejiang University, Hangzhou/CN浙江大学医学院附属第一医院[20]ChongqingCancer Hospital, Chongqing/CN[21]Affiliated Cancer Hospital of XinjiangMedical University, Wulumuqi/CN[22]Harbin Medical University CancerHospital, Haerbin/CN[23]The First Affiliated Hospital of ShantouUniversity Medical College, Shantou/CN[24]The Second AffiliatedHospital of Nanchang University, Nanchang/CN[25]The SecondAffiliated Hospital of Zhejiang University, Hangzhou/CN,[26]FujianProvicial Cancer Hospital, Fuzhou/CN[27]Beijing Friendship Hospital,Capital Medical University, Beijing/CN首都医科大学附属北京友谊医院[28]Tianjin Medical UniversityGeneral Hospital, Tianjin/CN[29]Thoracic Oncology, Liaoning CancerHospital, Shenyang/CN[30]The Affiliated Hospital of QingdaoUniversity, Qingdao/CN[31]Fourth Hospital of Hebei MedicalUniversity, Shijiazhuang/CN[32]The Affiliated Hospital of XuzhouMedical University, Xuzhou/CN
第一作者单位：[1]TianjinMedical University Cancer Institute and Hospital, Tianjin, China, Tianjin/CN
推荐引用方式(GB/T 7714)：
Li K.,Wang J.,Han B.,et al.Impact Factor Analysis for Efficacy and Prognosis of Anlotinib in NSCLC as Third-Line Treatment: Data from Trial ALTER 0303[J].JOURNAL of THORACIC ONCOLOGY.2017,12(11):S2236-S2236.doi:10.1016/j.jtho.2017.09.1528.
APA：
Li, K.,Wang, J.,Han, B.,Zhao, Y.,Wang, Q....&Wang, H..(2017).Impact Factor Analysis for Efficacy and Prognosis of Anlotinib in NSCLC as Third-Line Treatment: Data from Trial ALTER 0303.JOURNAL of THORACIC ONCOLOGY,12,(11)
MLA：
Li, K.,et al."Impact Factor Analysis for Efficacy and Prognosis of Anlotinib in NSCLC as Third-Line Treatment: Data from Trial ALTER 0303".JOURNAL of THORACIC ONCOLOGY 12..11(2017):S2236-S2236
医学